Matches in Wikidata for { <http://www.wikidata.org/entity/Q62054857> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- Q62054857 description "assaig clínic" @default.
- Q62054857 description "clinical trial" @default.
- Q62054857 description "clinical trial" @default.
- Q62054857 description "clinical trial" @default.
- Q62054857 description "clinical trial" @default.
- Q62054857 description "ensaio clínico" @default.
- Q62054857 description "ensayo clínico" @default.
- Q62054857 description "ensayu clínicu" @default.
- Q62054857 description "essai clinique" @default.
- Q62054857 description "klinisch onderzoek" @default.
- Q62054857 description "клінічне випробування" @default.
- Q62054857 description "临床试验" @default.
- Q62054857 name "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer" @default.
- Q62054857 type Item @default.
- Q62054857 label "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer" @default.
- Q62054857 prefLabel "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer" @default.
- Q62054857 P1132 Q62054857-F2003866-DB47-40D6-98EE-7CA1A782F000 @default.
- Q62054857 P1476 Q62054857-30CF9D46-7A4B-4776-A3F8-1122DE155010 @default.
- Q62054857 P17 Q62054857-063A03CE-D1C8-4420-938E-CB800F963CFF @default.
- Q62054857 P17 Q62054857-0C2E4CAE-D7C1-4BAE-8351-22A5F8B7784A @default.
- Q62054857 P17 Q62054857-1F951DB5-7288-46A2-ABCE-364813FA4E6E @default.
- Q62054857 P17 Q62054857-21B002F4-C80F-48C8-A76C-2647C9D65F5A @default.
- Q62054857 P17 Q62054857-26CA2839-3F90-42DD-AE42-D039338B07F6 @default.
- Q62054857 P17 Q62054857-2FF1C03D-CF1A-42C0-9FBC-83D71A6E793D @default.
- Q62054857 P17 Q62054857-3EFB68F7-79A9-4487-8241-722EF1D8ACFA @default.
- Q62054857 P17 Q62054857-5D99A0CE-5F19-4E07-BFBD-6570317F6283 @default.
- Q62054857 P17 Q62054857-611E46C5-7C64-4A12-B0A6-722CCFF6CA5E @default.
- Q62054857 P17 Q62054857-8EEF1731-80B6-48F2-8D9C-CA265B1F0CC2 @default.
- Q62054857 P17 Q62054857-A72D1020-3918-4C03-AAE7-C2EDAD230AA4 @default.
- Q62054857 P17 Q62054857-AF3395BC-ED55-4FCF-84E2-4E9985F86DA6 @default.
- Q62054857 P17 Q62054857-D1C64C37-1E79-4C06-BDDD-1C989B85AA75 @default.
- Q62054857 P17 Q62054857-E01EB312-EE3F-4C03-BCAD-02960BA668CE @default.
- Q62054857 P17 Q62054857-E7987D2F-5E39-4DB6-A587-7865B8CE29B8 @default.
- Q62054857 P17 Q62054857-E854B3F4-47CE-4C44-B774-9F1730F99860 @default.
- Q62054857 P1813 Q62054857-1FF579D6-8D66-46E0-9CA8-183BBBE11D66 @default.
- Q62054857 P2899 Q62054857-B3F4C6A3-3088-4C17-9C9B-B4F464C11C93 @default.
- Q62054857 P3098 Q62054857-C0D8D2CC-2E38-4532-B250-CC0C0CADE835 @default.
- Q62054857 P31 Q62054857-900C1B3C-C197-4C3D-9CBB-1511A83B6D1E @default.
- Q62054857 P4135 Q62054857-0A0394C7-4F53-42A7-A4CE-484993035AF7 @default.
- Q62054857 P4844 Q62054857-1773C641-6B34-4F39-B5F4-69A94D7BECC7 @default.
- Q62054857 P4844 Q62054857-53808160-7813-4EB3-89D9-1D5C710888C1 @default.
- Q62054857 P4844 Q62054857-63A43544-984D-4C16-85E2-88A943F32AAA @default.
- Q62054857 P4844 Q62054857-A6B2B3C5-1F55-463D-BC92-45D67DBC8FD1 @default.
- Q62054857 P580 Q62054857-426C3395-1839-4804-8D78-3DF07D6C1C17 @default.
- Q62054857 P582 Q62054857-9EB0F41D-0A5E-4912-B9F6-816C042DEE7C @default.
- Q62054857 P6099 Q62054857-29CEDCB7-C64C-4628-9F2B-81BCDED945EC @default.
- Q62054857 P8005 Q62054857-6C529D08-B48D-4792-9A05-E6C9AB501F4B @default.
- Q62054857 P859 Q62054857-76385002-90EA-4EF9-AFE3-2CA711551FBB @default.
- Q62054857 P1132 "+885" @default.
- Q62054857 P1476 "A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer" @default.
- Q62054857 P17 Q155 @default.
- Q62054857 P17 Q16 @default.
- Q62054857 P17 Q17 @default.
- Q62054857 P17 Q219 @default.
- Q62054857 P17 Q28 @default.
- Q62054857 P17 Q29 @default.
- Q62054857 P17 Q30 @default.
- Q62054857 P17 Q36 @default.
- Q62054857 P17 Q38 @default.
- Q62054857 P17 Q408 @default.
- Q62054857 P17 Q43 @default.
- Q62054857 P17 Q801 @default.
- Q62054857 P17 Q865 @default.
- Q62054857 P17 Q869 @default.
- Q62054857 P17 Q881 @default.
- Q62054857 P17 Q928 @default.
- Q62054857 P1813 "NILE" @default.
- Q62054857 P2899 "+18" @default.
- Q62054857 P3098 "NCT03682068" @default.
- Q62054857 P31 Q30612 @default.
- Q62054857 P4135 "+99" @default.
- Q62054857 P4844 Q412415 @default.
- Q62054857 P4844 Q414143 @default.
- Q62054857 P4844 Q415588 @default.
- Q62054857 P4844 Q7838098 @default.
- Q62054857 P580 "2018-09-27T00:00:00Z" @default.
- Q62054857 P582 "2022-04-27T00:00:00Z" @default.
- Q62054857 P6099 Q42824827 @default.
- Q62054857 P8005 Q76649708 @default.
- Q62054857 P859 Q731938 @default.